BioSpace News Archive

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy volunteers.

Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, announced that the first patient has been dosed in the company’s global Phase 1/2 clinical trial program for PBGM01

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) (“4D”, the “Company” or, together with its subsidiaries, the “Group”), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce the final results for the Group for the year ended 31 December 2020.

Carrus, a leading integrated technology platform that provides training solutions to the high-growth healthcare sector, announced today it has completed the acquisition of Archetype Innovations (“Archetype”)

Transaction includes TIBSOVO®, co-commercialization responsibilities for Bristol Myers Squibb’s IDHIFA® as well as a strong oncology pipeline of Phase 3 and early-stage assets

- Objectives of KIDCARES10 Study (KIg10 in peDiatric subjects: effiCacy, sAfety and phaRmacokinEticS of a 10% IG) a phase III, open-label, prospective, multi-center study are to assess the efficacy, safety, and pharmacokinetics of a 10 percent intravenous immunoglobulin (IVIG) in pediatric patients aged 2 to 17 years and affected by primary immunodeficiency disease (PI)

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced the sale of its minority share in Q 2 Solutions to IQVIA (NYSE: IQV)

Athersys, Inc. (NASDAQ: ATHX) announced today that Mr. Ivor Macleod, Chief Financial Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Wednesday, April 14, 2021 at 1:30 pm EDT.

Palantir Technologies (NYSE:PLTR) today issued additional details about the Palantir Foundry capabilities it will be highlighting in its Life Sciences demo at “Double Click” on Wednesday, April 14, 2021, at 11:00am ET.

Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced the signing of an agreement with Aytu BioPharma